Skip to content
Review Open access

THE ASSOCIATION BETWEEN THE HIGH-FLOW NASAL CANNULA TECHNIQUE DURING BRONCHOSCOPY AND THE MAINTENANCE OF PERIPHERAL OXYGEN SATURATION (SPO₂): A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES

Oct 2026 · The Indonesian Journal of General Medicine · 0 citations

TL;DR

The benefit of HFNC was consistent in direction across sedation depth, procedure type, baseline risk and comparator device, although heterogeneity in magnitude was substantial and was driven chiefly by trials with matched nominal FiO₂ or very high control-arm risk.

Abstract

Introduction: Peri-procedural hypoxaemia is the most frequent physiological complication of flexible bronchoscopy and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), particularly under procedural sedation, bronchoalveolar lavage (BAL) and in patients with limited respiratory reserve. High-flow nasal cannula (HFNC) delivers heated, humidified gas at up to 60–80 L/min with a stable fraction of inspired oxygen (FiO₂), nasopharyngeal dead-space washout and a flow-dependent positive airway pressure. We aimed to quantify the association between HFNC use during bronchoscopy and the maintenance of peripheral oxygen saturation (SpO₂), with emphasis on evidence published in the last 15 years.1–3 Methods: The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Randomised controlled trials (RCTs), cohort, case–control, cross-sectional and other prospective or retrospective observational studies comparing HFNC with conventional oxygen therapy (COT), non-invasive ventilation (NIV) or different HFNC flows during bronchoscopy were eligible.4–6 Results: Thirty-two primary studies (23 RCTs and 9 observational/non-randomised studies; 4,572 participants; 2012–2026) were included. In 12 adult RCTs (2,318 participants), HFNC reduced intraprocedural desaturation (SpO₂ < 90%) from 39.9% to 15.0% (risk ratio [RR] 0.34, 95% CI 0.25–0.47; I² = 72%; prediction interval 0.12–0.95), corresponding to 262 fewer events per 1,000 patients and a number needed to treat of 3.8. Including the PROSA-2 trial and two observational studies (odds ratio 0.20, 95% CI 0.14–0.28) did not change the inference. HFNC increased nadir SpO₂ by 4.95 percentage points (95% CI 2.89–7.00; five RCTs), reduced procedure interruption (RR 0.39, 0.28–0.54; I² = 13%), airway manoeuvres or support escalation (RR 0.40, 0.24–0.67) and severe hypoxaemia/advanced rescue (RR 0.31, 0.16–0.63). A monotonic flow–response relationship was observed, with a reported ED₉₅ of approximately 43 L/min. In moderate-to-severe hypoxaemic respiratory failure, NIV provided better oxygenation than HFNC. The effect was robust across all sensitivity analyses; certainty was moderate for desaturation and procedure interruption.7–13 Discussion: The benefit of HFNC was consistent in direction across sedation depth, procedure type (EBUS-TBNA vs. non-EBUS bronchoscopy), baseline risk and comparator device, although heterogeneity in magnitude was substantial and was driven chiefly by trials with matched nominal FiO₂ or very high control-arm risk. Neutral trials under conscious sedation and matched FiO₂ suggest that part of the benefit derives from superior and more stable oxygen delivery, while physiological studies support additional contributions from preserved end-expiratory lung volume and dead-space washout.14–16 Conclusion: HFNC during bronchoscopy is associated with clinically meaningful preservation of SpO₂, fewer hypoxaemic events and fewer procedure interruptions, with moderate certainty. HFNC at ≥ 45–60 L/min should be preferred for sedated, prolonged or BAL-containing procedures and for patients at increased risk, whereas NIV/CPAP remains preferable in established moderate-to-severe hypoxaemic respiratory failure. Adequately powered, blinded-outcome multicentre trials with standardised desaturation definitions and patient-important endpoints are required.2,17

Read PDF

Similar papers

Open access Oct 2026

High-Flow Nasal Oxygen and Desaturation During Deep Sedation for Colonoscopy in Patients at Increased Respiratory Risk: A Propensity Score-Matched Cohort Study

Background/Objectives: Hypoxaemia is the most common adverse event during procedural sedation. High-flow nasal oxygen (HFNO) may reduce desaturation through continuous positive airway pressure, anatomical dead space washout, and stable FiO2 delivery. This retrospective cohort study assessed the association between two...

M. Á. Alonso-Fernández, Ó. Martínez-González, Mónica García-Alonso et al. · 0 citations
Meta-analysis Open access Sep 2026

High-flow nasal cannula versus standard oxygen therapy for adult acute hypoxemic respiratory failure: a systematic review and meta-analysis with trial sequential analysis and GRADE assessment

High-flow nasal cannula (HFNC) is widely used as an early respiratory support strategy for adults with acute hypoxemic respiratory failure (AHRF). Although HFNC may reduce the risk of endotracheal intubation, it remains uncertain whether the available evidence is sufficiently mature and whether this potential benefit t...

Liang-Dong Zhu, Xun Yang, Jing Tan et al. · 0 citations
Oct 2026

Comparison of the Effects of High-Flow Nasal Cannula Oxygen and Jet Ventilation Techniques.

While HFNC offers an ideal tubeless field for short interventions, its use is limited by time-dependent hypercapnia and progressive respiratory acidosis; for longer endolaryngeal procedures, HFJV is preferred to maintain ventilatory and metabolic homeostasis.

Seda Özdağlı, M. Canbaz, E. Çamcı et al. · 0 citations
Open access Oct 2026

High-flow nasal cannula versus high-velocity nasal insufflation for weaning from mechanical ventilation in respiratory intensive care unit: a randomized clinical trial

High-velocity nasal insufflation and High-flow nasal cannula initiated immediately postextubation versus NIV represent effective and better-tolerated alternatives to NIV for postextubation respiratory support, with similar short-term clinical outcomes.

Montaser G. Ahmed, A. Hussein, W. Khaleel · 0 citations
Open access Oct 2026

High-Flow Nasal Oxygenation Is Associated with Improved Respiratory Stability During Moderate Multimodal Analgosedation for Pars Plana Vitrectomy: A Randomized Controlled Trial

Background/Objectives: High-flow nasal oxygenation (HFNO) may improve respiratory stability during procedural sedation, but treatment-associated differences across patient risk categories remain uncertain. We compared HFNO with low-flow nasal oxygenation (LFNO) during moderate multimodal analgosedation (MMAS) for pars...

Anita Z. Vuković, Tomislav Jukić, Marija Stanfel et al. · 0 citations
Review Open access Sep 2026

High‐Flow Nasal Oxygen Versus Conventional Oxygen Therapy and Non‐Invasive Ventilation for Acute Respiratory Failure in the Emergency Department: A Systematic Review and Meta‐Analysis

This systematic review and meta‐analysis compares the use of high‐flow nasal oxygen (HFNO) with conventional oxygen therapy (COT) and non‐invasive ventilation (NIV) in the management of acute respiratory failure (ARF) in the emergency department (ED). A comprehensive search of relevant sources was undertaken. Randomise...

Rupert Phillips, Adrianna E. Klejnotowska, Harry Claxton et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.